Drugs / ZGGS18
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06938880 | May 2025 → May 2027 expected | neoplasm | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05584800 | Nov 2022 → Nov 2026 expected | — | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZGGS18 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05584800 ↗ |
| Route | Intravenous | “intravenous infusion” NCT05584800 ↗ |